for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arbutus Biopharma Corp

ABUS.OQ

Latest Trade

2.37USD

Change

-0.02(-0.84%)

Volume

27,550

Today's Range

2.37

 - 

2.40

52 Week Range

0.82

 - 

4.76

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.39
Open
2.38
Volume
27,550
3M AVG Volume
12.79
Today's High
2.40
Today's Low
2.37
52 Week High
4.76
52 Week Low
0.82
Shares Out (MIL)
56.85
Market Cap (MIL)
136.44
Forward P/E
-1.25
Dividend (Yield %)
--

Next Event

Q4 2019 Arbutus Biopharma Corp Earnings Release

Latest Developments

More

Foresite Capital Fund Reports Passive Stake In Arbutus Biopharma

Arbutus Reports Third Quarter 2019 Financial Results

Arbutus Biopharma Q2 Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arbutus Biopharma Corp

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Industry

Biotechnology & Drugs

Contact Info

100-8900 Glenlyon Pky

+1.604.4193200

http://www.arbutusbio.com/

Executive Leadership

Frank M. Torti

Independent Chairman of the Board

William H. Collier

President, Chief Executive Officer, Director

David C. Hastings

Chief Financial Officer

Elizabeth Howard

Executive Vice President, Chief Compliance Officer, General Counsel

Michael Joseph Sofia

Chief Scientific Officer

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-4.640

2017

-1.790

2018

-1.210

2019(E)

-1.918
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.47
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-86.35
Return on Equity (TTM)
-81.24

Latest News

Latest News

BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology

* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

BRIEF-Arbutus Announces Departure Of CFO Bruce Cousins

* ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO

BRIEF-Arbutus Consolidates HBV Business Around Warminster, PA Site

* ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

BRIEF-Arbutus Biopharma Q2 loss per share $0.33

* Arbutus announces corporate update and second quarter 2017 financial results

BRIEF-Arbutus expects to take two experimental hep B drugs into human studies by mid-2018 - CEO

* Arbutus Biopharma expects to take two of its preclinical hep B drugs-in-development into human studies by mid-2018 - ceo Further company coverage:

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

BRIEF-RTW Investments LP reports 5 pct passive stake in Arbutus Biopharma

* RTW Investments LP reports 5.0 percent passive stake in Arbutus Biopharma Corp as of May 10 - SEC filing Source text for Eikon: (http://bit.ly/2qsXKpC) Further company coverage:

BRIEF-Arbutus reports Q1 non-GAAP loss per share $0.29

* Arbutus announces corporate update and first quarter 2017 financial results

BRIEF-Arbutus Biopharma says Arbutus Injunction survives attempted appeal by Acuitas

* Arbutus biopharma corp - arbutus injunction survives attempted appeal by acuitas

BRIEF-Arbutus announces year-end 2016 financial results

* Arbutus Biopharma Corp - as at Dec 31, 2016, co had cash, cash equivalents, restricted investments of $143.2 million versus $191.4 million at December 31, 2015 Source text for Eikon: Further company coverage:

BRIEF-Arbutus licenses LNP delivery technology to Alexion

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

BRIEF-Arbutus Biopharma Corp files for non-timely 10-K

* Arbutus Biopharma Corp files for non-timely 10-k - sec filing Source text - http://bit.ly/2mNW5az Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up